Doxorubicin and cisplatin induced cognitive impairment: The possible mechanisms and interventions

• Published in: Experimental neurology 2020-02, Vol.324, p.113118, Article 113118
• Main Authors: Ongnok, Benjamin, Chattipakorn, Nipon, Chattipakorn, Siriporn C.
• Format: Article
• Language: English
• Subjects: Chemotherapy; Cisplatin; Cognition; Doxorubicin; Neurotoxicity
• ISSN: 0014-4886; 1090-2430
• DOI: 10.1016/j.expneurol.2019.113118

Chemotherapy has significantly increased the number of cancer survivors. However, chemotherapy itself carries various adverse effects that limit the efficacy of treatment and quality of life of the cancer patients. Most patients who have received chemotherapy report some cognitive deficit characterized by dysfunction in memory, learning, concentration, and reasoning. The phenomenon of cognitive decline developed from chemotherapy treatment is referred to as chemotherapy-induced cognitive impairment (CICI) or chemobrain. The two most common cancers occurring worldwide are lung and breast cancer. The predominant chemotherapeutic drugs used to treat lung and breast cancer are doxorubicin and cisplatin. There is evidence to suggest that both drugs potentially induce chemobrain. The evidence around the proposed pathogenesis of chemobrain caused by these two drugs is inconsistent. Understanding the underlying mechanisms involved in the development of chemobrain would aid in the prevention or treatment of the adverse effects of chemotherapy on brain. This review will summarize and discuss controversial findings and possible mechanisms involved in the development of chemobrain and the interventions which could limit it from in vitro, in vivo, and clinical studies. [Display omitted]